{"id":1004261,"date":"2026-09-17T11:17:48","date_gmt":"2026-09-17T15:17:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-expands-ultrasome-intellectual-property-portfolio-with-new-u-s-provisional-patent-filing\/"},"modified":"2026-09-17T11:17:48","modified_gmt":"2026-09-17T15:17:48","slug":"creative-medical-technology-holdings-inc-expands-ultrasome-intellectual-property-portfolio-with-new-u-s-provisional-patent-filing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-expands-ultrasome-intellectual-property-portfolio-with-new-u-s-provisional-patent-filing\/","title":{"rendered":"Creative Medical Technology Holdings, Inc. Expands Ultrasome\u2122 Intellectual Property Portfolio with New U.S. Provisional Patent Filing"},"content":{"rendered":"

\nNew Filing Seeks Broad Protection Around Creative Medical\u2019s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency, Manufacturing Controls and Additional Therapeutic Applications
\n<\/h2>\n
\n

PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the filing of a new U.S. provisional patent application designed to expand intellectual property protection surrounding Ultrasome\u2122, the Company\u2019s proprietary cell-free regenerative medicine platform.<\/p>\n

The newly filed application builds upon Creative Medical\u2019s existing regenerative medicine intellectual property and seeks protection across multiple aspects of the Ultrasome platform, including proprietary product composition, biological potency, manufacturing and quality-control methodologies, stability characteristics, delivery approaches and therapeutic applications.<\/p>\n

The filing is intended to strengthen the Company\u2019s long-term intellectual property position as Creative Medical advances Ultrasome beyond its initial osteoarthritis program and evaluates the platform\u2019s potential across additional areas of regenerative medicine.<\/p>\n

\n \u201cAs our understanding of the Ultrasome platform continues to advance, we believe it is important to protect not only its therapeutic applications, but also the underlying product characteristics, biological activity and manufacturing framework that distinguish the platform,\u201d said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. \u201cThis filing represents another step in building a broad intellectual property estate around what we believe can become a highly scalable cell-free regenerative medicine platform.\u201d<\/em>\n <\/p>\n

\n Building Intellectual Property Around Product Function, Not Simply Particle Identity<\/strong>\n <\/p>\n

Creative Medical\u2019s development strategy for Ultrasome incorporates both physical product characterization and biologically relevant functional testing designed to evaluate activity associated with tissue protection and regenerative signaling.<\/p>\n

The newly filed provisional patent application seeks intellectual property protection around multiple aspects of this approach, including methods intended to characterize the biological activity and consistency of manufactured product.<\/p>\n

Management believes that integrating product composition, functional potency and manufacturing control may provide important differentiation as the field of extracellular-vesicle and secretome-based therapeutics continues to evolve.<\/p>\n

The patent application also includes intellectual property directed toward methods for evaluating changes in product biological activity that may not be reflected by particle measurements alone.<\/p>\n

\n \u201cA central component of our development strategy is establishing reproducible biological activity across manufactured product,\u201d Warbington added. \u201cWe believe that connecting manufacturing, product characterization and functional performance is important both scientifically and strategically as we advance this platform.\u201d<\/em>\n <\/p>\n

\n Builds on Previously Announced Ultrasome\u2122 Knee Osteoarthritis Program<\/strong>\n <\/p>\n

The new patent filing follows Creative Medical\u2019s previously announced pilot study evaluating Ultrasome in patients with knee osteoarthritis.<\/p>\n

As announced in April 2026, the study reported that approximately 93% of participants demonstrated clinically meaningful improvements in mobility and pain, and no serious adverse events were reported.<\/p>\n

The Company continues to view osteoarthritis as an important initial application for Ultrasome while exploring the broader potential of the platform across regenerative medicine.<\/p>\n

The new provisional filing includes intellectual property intended to preserve development flexibility for musculoskeletal and cartilage disorders as well as selected clinical applications. These additional applications remain in various stages of research and development and should not be interpreted as evidence of clinical efficacy or regulatory approval in those indications.<\/p>\n

\n Extending a GMP-Based Regenerative Medicine Platform<\/strong>\n <\/p>\n

Ultrasome is being developed from Creative Medical\u2019s proprietary Olastrocel\u2122\u00a0regenerative medicine platform.<\/p>\n

The underlying cellular source is derived from an independently validated Good Manufacturing Practice master cell bank, with manufacturing and quality information maintained within a U.S. Food and Drug Administration Drug Master File.<\/p>\n

A Drug Master File is a confidential regulatory submission containing manufacturing and quality information and does not itself constitute FDA approval, clearance or authorization of a therapeutic product.<\/p>\n

Creative Medical believes the ability to leverage a controlled cellular starting material across both cell-based and cell-free programs may support future manufacturing scalability, product consistency and expansion of its regenerative medicine pipeline.<\/p>\n

\n Expanding Creative Medical\u2019s Intellectual Property Portfolio<\/strong>\n <\/p>\n

The new application is part of Creative Medical\u2019s strategy of building intellectual property protection around multiple layers of its regenerative medicine technologies, including:<\/p>\n